MARKET

ENTA

ENTA

Enanta Pharmaceuticals Inc
NASDAQ
9.76
+0.42
+4.50%
After Hours: 9.76 0 0.00% 16:02 12/01 EST
OPEN
9.40
PREV CLOSE
9.34
HIGH
9.87
LOW
9.11
VOLUME
213.94K
TURNOVER
0
52 WEEK HIGH
62.06
52 WEEK LOW
8.08
MARKET CAP
205.54M
P/E (TTM)
-1.5294
1D
5D
1M
3M
1Y
5Y
Enanta: Multiple Shots On Goal For RSV Makes This A Must Watch
Seeking Alpha · 2d ago
How Much Upside is Left in Enanta Pharmaceuticals (ENTA)? Wall Street Analysts Think 88.23%
NASDAQ · 5d ago
Weekly Report: what happened at ENTA last week (1120-1124)?
Weekly Report · 5d ago
Enanta Pharmaceuticals Inc: Registration statement under Securities Act of 1933
Press release · 11/22 23:09
Enanta Pharmaceuticals Inc: Statement of changes in beneficial ownership of securities
Press release · 11/22 23:09
Enanta Pharmaceuticals Inc: Annual report
Press release · 11/22 22:04
Enanta Pharmaceuticals files for a $150M mixed shelf offering
Enanta pharmaceuticals files for a $150m mixed shelf offering to raise up to $150 million. The company filed a prospectus related to the offering on nov. 22. This prospectus is not an offer to sell these securities in the u.s. .
Seeking Alpha · 11/22 21:50
Oppenheimer Maintains Perform on Enanta Pharma, Lowers Price Target to $21
Benzinga · 11/22 18:47
More
About ENTA
Enanta Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in the discovery and development of small molecule drugs, with an emphasis on treatments for viral infections. Its primary wholly owned research and development programs are in virology, namely respiratory syncytial virus (RSV), SARS-CoV-2, Hepatitis B virus (HBV) and Human metapneumovirus (hMPV). The Company has discovered glecaprevir, the second of two protease inhibitors discovered and developed for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is a co-formulated direct-acting antiviral (DAA), combination treatment for HCV, which is marketed under the tradenames MAVYRET and MAVIRET. Its lead clinical candidate for the treatment of chronic infection with HBV, is EDP-514. Its lead clinical candidate for COVID-19 is EDP-235. The Company's clinical stage program for RSV, with two compounds in clinical trials includes EDP-938 and EDP-323.

Webull offers Enanta Pharmaceuticals Inc stock information, including NASDAQ: ENTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENTA stock methods without spending real money on the virtual paper trading platform.